Molecular subsetting of interferon pathways in Sjögren's syndrome

Arthritis and Rheumatology

Volumn 67, Issue 9, 2015, Pages 2437-2446

  Hall, John C ^a   Baer, Alan N ^a   Shah, Ami A ^a   Criswell, Lindsey A ^b,c,d   Shiboski, Caroline H ^c   Rosen, Antony ^a   Casciola Rosen, Livia ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Rosalind Russell Ephraim P Engleman Rheumatology Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; GAMMA INTERFERON; INTERFERON; SS-A ANTIBODIES;

ADULT; ANTIBODY TITER; ARTICLE; CELL LYSATE; CONTROLLED STUDY; DRY EYE; FEMALE; HUMAN; HYPER IGE SYNDROME; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; SALIVARY GLAND; SALIVARY GLAND BIOPSY; SJOEGREN SYNDROME; AGED; CASE CONTROL STUDY; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; MINOR SALIVA GLAND; PATHOPHYSIOLOGY; XEROPHTHALMIA; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOBLOTTING; INTERFERON TYPE I; INTERFERON-GAMMA; LEUKOPENIA; MALE; MIDDLE AGED; PHENOTYPE; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME; XEROPHTHALMIA; XEROSTOMIA;

EID: 84940118357     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39204     Document Type: Article

References (28)

1. Ramos-Casals M, Tzioufas AG, Font J., Primary Sjögren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64: 347-54.
2. Fox PC., Autoimmune diseases and Sjögren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007; 1098: 15-21.
3. Jonsson R, Bolstad AI, Brokstad KA, Brun JG., Sjögren's syndrome: a plethora of clinical and immunological phenotypes with a complex genetic background. Ann N Y Acad Sci 2007; 1108: 433-47.
4. Mariette X, Gottenberg JE., Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010; 22: 471-7.
5. Daniels TE, Whitcher JP., Association of patterns of labial salivary gland inflammation with keratoconjunctivitis sicca: analysis of 618 patients with suspected Sjögren's syndrome. Arthritis Rheum 1994; 37: 869-77.
6. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al., Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52: 1185-95.
7. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI., Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52: 1534-44.
8. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-5.
9. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al., Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-23.
10. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al., Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56: 3784-92.
11. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al., Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A 2006; 103: 2770-5.
12. Hall JC, Casciola-Rosen L, Berger AE, Kapsogeorgou EK, Cheadle C, Tzioufas AG, et al., Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A 2012; 109: 17609-14.
13. Mavragani CP, Crow MK., Activation of the type I interferon pathway in primary Sjögren's syndrome. J Autoimmun 2010; 35: 225-31.
14. Chiche L, Jourde-Chiche N, Whalen E, Presnell S, Gersuk V, Dang K, et al., Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol 2014; 66: 1583-95.
15. Malladi AS, Sack KE, Shiboski SC, Shiboski CH, Baer AN, Banushree R, et al., Primary Sjögren's syndrome as a systemic disease: a study of participants enrolled in an international Sjögren's syndrome registry. Arthritis Care Res (Hoboken) 2012; 64: 911-8.
16. Daniels TE, Criswell LA, Shiboski C, Shiboski S, Lanfranchi H, Dong Y, et al., for the Sjögren's International Collaborative Clinical Alliance Research Groups. An early view of the international Sjögren's syndrome registry. Arthritis Rheum 2009; 61: 711-4.
17. Daniels TE, Cox D, Shiboski CH, Schiodt M, Wu A, Lanfranchi H, et al., for the Sjögren's International Collaborative Clinical Alliance Research Groups. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjögren's syndrome among 1,726 registry participants. Arthritis Rheum 2011; 63: 2021-30.
18. Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al., for the Sjögren's International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012; 64: 475-87.
19. Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, et al., Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601.
20. De Hoon MJ, Imoto S, Nolan J, Miyano S., Open source clustering software. Bioinformatics 2004; 20: 1453-4.
21. Eisen MB, Spellman PT, Brown PO, Botstein D., Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95: 14863-8.
22. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM., Characteristics of the minor salivary gland infiltrates in Sjögren's syndrome. J Autoimmun 2010; 34: 400-7.
23. Petri M, Wallace DJ, Spindler A, Chindalore V, Kalunian K, Mysler E, et al., Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013; 65: 1011-21.
24. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al., for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63: 3918-30.
25. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al., Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-33.
26. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al., Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.
27. Solomon B, Varella-Garcia M, Camidge DR., ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol 2009; 4: 1450-4.
28. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al., Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.